Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Anamnestic Immune Response in Healthy 4 to 7 Year-old Children After a Primary Vaccination Series With Either HEXAVAC® or INFANRIX®-HEXA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy child of 4 to 7 years of age of either gender,~* Child vaccinated with 2 doses of HEXAVAC® during the first 6 months of life and with a 3rd dose of HEXAVAC® before the end of the second year of life or Child vaccinated with 2 doses of INFANRIX®-HEXA during the first 6 months of life and with a 3rd dose of INFANRIX®-HEXA before the end of the second year of life,~* Informed consent form signed by the parent(s) or by the legal representative.~* Parent(s) or legal representative able to understand and comply with the study procedures.~Exclusion Criteria:~* Any recent (\<=3 days) history of febrile illness prior to vaccination,~* Receipt of more than 3 doses of any Hepatitis B containing vaccine, either alone or in any combination,~* History of clinical or serological-confirmed diagnosis of infection due to hepatitis B,~* History or current close contact with known carriers of hepatitis B virus,~* Prior known sensitivity/allergy to any component of the study vaccines,~* Any known blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the haematopoietic and lymphatic systems,~* Any severe thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injection,~* Any immune impairment or humoral/cellular deficiency or depressed immunity,~* Any recent (\<=30 days) long-term (\>=14 days) administration of systemic corticosteroids given daily or on alternate days at \>=20 mg/day prednisone equivalent or scheduled administration through Visit 2,~* Any receipt (\<=3 months) of immunoglobulins or blood-derived products, or scheduled administration through Visit 2,~* Any recent (\<=14 days) receipt of an inactivated vaccine or scheduled administration through Visit 2,~* Any recent (\<=28 days) receipt of a live vaccine or scheduled administration through Visit 2

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 7 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).